Supplemental Figure 5. Combined PIM/MEK Inhibition Restores Sensitivity to AZD1208 in NF1 Knock out Cell Lines from PIM Kinases Are a Potential Prognostic Biomarker and Therapeutic Target in Neuroblastoma

(A-F) The indicated cell lines were plated in 6-well plates and treated with AZD1208, cobimetinib, MK2206 or the combination. Drug-containing medium was refreshed every 3 days. Cells were fixed, stained, and scanned when untreated wells reached confluency (n=3).